中关村：比索洛尔氨氯地平片上市许可申请获受理

Core Viewpoint - Zhongguancun announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. has had its application for the listing permit of Bisoprolol Amlodipine Tablets accepted by the National Medical Products Administration, which is a combination therapy for hypertension treatment [1] Group 1 - The drug is a fixed-dose combination formulation of fumarate bisoprolol 5mg and amlodipine besylate (calculated as amlodipine) 5mg [1] - The project has accumulated research and development expenses of 6.0798 million yuan [1] - Shandong Huasu will actively promote the subsequent review work, and if the listing permit is successfully obtained, it will enhance its market competitiveness [1]